Loading stock…

Chugai Pharmaceutical Co., Ltd. (4519) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Chugai Pharmaceutical Co., Ltd.

4519Market cap $63BPrice $38.7

Country🇯🇵Japan

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures prescription drugs, with a focus on cancer treatments and rare diseases. Partners exclusively with Roche for global drug development, giving it access to blockbuster medications most Japanese pharma companies can't touch.

In Bastion Portfolios?

52W Return-14%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-6%2

Revenue Forecast

Rev CAGR (1y)+9%6

Rev CAGR (3y)+9%7

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1+14%7

EPS Growth Y+2+15%7

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin48%10

Net Income Margin35%9

Free Cash Flow Margin30%9

Debt

Net Debt/EBITDA-1.410

Efficiency

ROE23%8

ROA20%10

Earnings Stability55

GEAR+STRONG83

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)164

P/BV5.03

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd137

Yield

Free Cash Flow Yield4.0%6

Dividend Yieldna–

Momentum

Short term

1 month return-7%4

3 month return-17%2

YTD return-25%2

Mid term

Price vs 52wHigh58%2

1 year return-13%3

Long term

3 year return+47%5

5 year return+75%7

Risk Shield

Price Risk

Beta0.76

Volatility41%4

Free Cash Flow

Free Cash Flow Margin30%9

Free Cash Flow Yield4.0%6

Quality

ROCE32%10

Earnings Stability55

Net Debt/EBITDA-1.410

02Growth

Is it actually growing, and how fast?

4519Chugai Pharmaceutical Co.

Revenue FY25$8.0B

GROWTH RATING↗

AVERAGE57 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%2

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+15%7

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

Earnings are set to grow in step with sales (EPS about 14%/yr vs revenue 9%/yr).

WATCH

A mid-pack grower, ahead of 57% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Revenue fell 6%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK20 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-17%2

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high58%2

1-year return-13%3

3-year return+47%5

5-year return+75%7

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+47% over three years and +75% over five), roughly average for the market.

Returns sit at the market level over the past month (-7%).

WEAKNESSES

It's down 13% over the past year, now 42% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-17%) and so far this year (-25%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Chugai. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

4519Chugai Pharmaceutical Co.

Revenue FY25$8.0B

GROWTH RATING↗

AVERAGE57 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-6%2

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+9%7

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+15%7

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 9%/yr from here.

Earnings are set to grow in step with sales (EPS about 14%/yr vs revenue 9%/yr).

WATCH

A mid-pack grower, ahead of 57% of companies worldwide.

Revenue is set to grow 9%/yr over the next 3 years, a little ahead of the market.6/10

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

WEAKNESSES

Revenue fell 6%/yr over the last 3 years, behind 80% of companies worldwide.2/10

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK20 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-17%2

YTD return-25%2

MID & LONG-TERM▾SCORE

% of 52-week high58%2

1-year return-13%3

3-year return+47%5

5-year return+75%7

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+47% over three years and +75% over five), roughly average for the market.

Returns sit at the market level over the past month (-7%).

WEAKNESSES

It's down 13% over the past year, now 42% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-17%) and so far this year (-25%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Chugai. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community